A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

Inclusion Criteria: * 18-65 years old (including boundary values), regardless of gender; * Screening requires virological , clinical or pathological evidence of hepatitis B virus infection for more than 6 months; HBsAg positive, HBeAg positive, ALT≤5×ULN at screening; * Never received nucleoside (acid) analog or interferon treatment, or previously received no more than 12 weeks of treatment but had discontinued therapy at least 6 months prior to the screening visit; * Ability to communicate effectively with researchers and understand and comply with the requirements of this study, understand and sign the informed consent form; * Male subjects with female partners who have fertility or female subjects of childbearing age are willing to voluntarily adopt effective contraceptive measures screening to within 3 months after leaving the group. Exclusion Criteria: * Pregnant (positive pregnancy test) or lactating women. * Co-infection with other viruses such as Hepatitis A Virus (HAV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), Hepatitis E Virus (HEV), Human Immunodeficiency Virus (HIV), Syphilis, etc.; * History of cirrhosis or evidence of significant fibrosis or cirrhosis before or during screening; * History of hepatocellular carcinoma (HCC) or suspected HCC before or during screening.; * History of malignant tumors within the past 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection; * Subjects with other chronic liver diseases, including but not limited to autoimmune liver disease, alcoholic liver disease, Wilson's disease, Gilbert syndrome, etc; * Previous organ or bone marrow transplantation; * Clinically significant abnormal laboratory test results at screening. * Poorly controlled thyroid diseases or clinically significant thyroid dysfunction; * Autoimmune diseases; * Significant systemic or major illnesses other than liver disease. * Any systemic anti-tumor or immunosuppressive therapy, or immunomodulatory therapy within 6 months prior to screening. * High-dose systemic corticosteroids use within 3 months prior to screening; * History of alcohol or drug abuse within the past year or excessive alcohol consumption. * History of blood transfusion within 2 months prior to screening; * History of allergy to investigational drug or its excipients. * Previously participated in the clinical trial of hepatitis B core protein allosteric modulators; * Participation in another clinical trial and receipt of an investigational drug within the following timeframes before the first dose in this study: 5 half-lives (if known) or twice the duration of the biological effect of the study treatment (if known), whichever is longer, or 90 days (if the half-life or duration is unknown); * History or condition of cardiovascular disease; * Any other condition deemed inappropriate for inclusion by the investigator.